What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Expert Opin Pharmacother. 2019 Jan;20(1):5-9. doi: 10.1080/14656566.2018.1543406. Epub 2018 Nov 6.

Authors

Gaia Giannone^{1

2}, Andrea Milani³, Elena Geuna³, Danilo Galizia³, Federica Biello³, Filippo Montemurro³

Affiliations

¹ a Medical Oncology , Candiolo Cancer Institute-FPO, IRCCS , Candiolo , Italy.
² b Medical School , University of Turin , Turin , Italy.
³ c Investigational and Clinical Oncology , Candiolo Cancer Institute-FPO, IRCCS , Candiolo , Italy.

PMID: 30396301
DOI: 10.1080/14656566.2018.1543406

No abstract available

Keywords: HER2; T-DM1; adjuvant; breast cancer; chemotherapy; lapatinib; metastatic; neratinib; pertuzumab; trastuzumab.

Publication types

Editorial